Member Info for Wilson63

Paul Eros platform strategy awuisvof Itis unique position complete system

Diseases what areas ajan expanding Covid variants Covid plus sepsis transplant then load of letters

Comms with shareholders best commercial interest eg we didn't give many media interviews purposely 62 last year 31 this year

Guidance for 2021 100 mil excl dhsc 2022 too early for targets.

Cash position div? Buy back? Continuity to invest building for post Covid

Gm summary
Strong growth Covid we also see
High quality acquisition

Can't personally get into q and a and not losing my link
Presubmitted question first dhsc lol

New contract 4.7 mil PROmate supplied under q's16/32 no update since June no fu

Expand beyond Covid
Will be downward price pressure going after more profitable products to mitigate this

Opex r and etc remarkable investment r and 1.6 mil 2020
Opex going forward 30 of revs

CASH conversion every 100 80cash flow upside corp tax patent box bla bla

M and a where we accelerate growth

James McCarthy

Culture very good within company
Development from small to big
High margin 70% gross
Ebidta 40 cash conversion 89%
Revenue

Going forward cross selling(missed an imp bit)
Gaining market share own sales and service
Doubled our team
Now in second phase us
3rd phase european
More req in a country we will target

Novacyt excellent track record
World recognise we want to br

5000> customers
>400 distributer

Guillermo
Educated in business management

Lft's on Covid graphic
Npt educational institutes on graph
Second quarter 3 x increase with five biggest private customers

Paul Eros

Q16/32's molecular diagnostics will continue to grow after Covid
Experts in pcr process
It-is significant strategic investment
PROmate outside labs development of PROmate initially for Covid now being developed for elsewhere

Exsig msg fully integrated solutions

Novacyt solutions can be deployed in airports etc and versalab
Focussing here not fighting big boys

Ajan reginauld
26 new assays by end of 2022 (Covid and non Covid)
Bioinformatics analyses 2mil a week
15 + trials in uk and Intl
More than 250 assays

Overview of market
28 new products since 2020
Next steps develop beyond Covid
Access better equip

Started

I'm in the waiting room I will report as we go along if points are worthy, if anybody is faster I'll stop posting so the board is not drowned gla.

21ats I shall leave you to ask your own questions then, I'd imagine anybody who's been invested for a reasonable period amount of time will be of the opinion the company has held off reinvesting (my opinion) until they have clarity re dhsc, of course if another oppurtunity like it-is((well done GM) at a great price I'm sure the company would still pile in.

B2 29.8 million of products/components/materials at the end of the year iirc.

21ats glad your business is better any you sleep better it's genuinely horrible, but there is no cash flow issue here in fact I shall ask that question if possible at the end of the webinair can't say fairer than that.

21ats I think the facts bare out that we had more revenues outwith the dhsc in fact virtually a 60/40 split in favour of non dhsc personally I do find that pretty exciting and shows the much criticised board have been doing an admiral job on that front,as ever.

Held.......Holding.......,Hold.

Morning Gizmo555 get those binoculars out.